453548-65-7

Basic information

• Product Name: 1-Imidazo[1,2-b]pyridazin-3-ylethanone
• Synonyms: Ethanone, 1-imidazo[1,2-b]pyridazin-3-yl- (9CI);Ethanone, 1-imidazo[1,2-b]pyridazin-3-yl-;1-Imidazo[1,2-b]pyridazin-3-ylethanone
• CAS NO: 453548-65-7
• Molecular Formula: C₈H₇N₃O
• Molecular Weight: 161.16
• EINECS: 604-604-1
• Product Categories: ACETYLGROUP
• Mol File: 453548-65-7.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Density: 1.33±0.1 g/cm3(Predicted)
• Refractive Index: 1.668
• PKA: 2.42±0.30(Predicted)
• CAS DataBase Reference: 1-Imidazo[1,2-b]pyridazin-3-ylethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Imidazo[1,2-b]pyridazin-3-ylethanone(453548-65-7)
• EPA Substance Registry System: 1-Imidazo[1,2-b]pyridazin-3-ylethanone(453548-65-7)

Safety Data

• Hazardous Substances Data: 453548-65-7(Hazardous Substances Data)

Usage

General Description

1-Imidazo[1,2-b]pyridazin-3-ylethanone is a chemical compound with the molecular formula C9H7N3O. It is a heterocyclic compound with a fused pyridazine and imidazole ring system, which gives it unique structural and chemical properties. 1-Imidazo[1,2-b]pyridazin-3-ylethanone is commonly used in organic synthesis as a building block for the preparation of various pharmacologically active compounds. It has potential applications in drug development and medicinal chemistry due to its diverse biological activities, including anti-inflammatory, anticancer, and antimicrobial properties. The synthesis and study of 1-Imidazo[1,2-b]pyridazin-3-ylethanone and its derivatives have attracted significant attention in the pharmaceutical industry for their potential as novel drug candidates with therapeutic applications.

InChI:InChI=1/C8H7N3O/c1-6(12)7-5-9-8-3-2-4-10-11(7)8/h2-5H,1H3

Upstream product

• 90734-71-7 1-{6-chloroimidazo[1,2-b]pyridazin-3-yl}ethan-1-one 
• 97674-02-7 tributyl(1-ethoxyvinyl)stannane 
• 18087-73-5 3-bromo-imidazo[1,2-b]pyridazine 
• 78-95-5 chloroacetone 
• 35053-54-4 N,N-dimethyl-N'-pyridazin-3-yl-formamidine 
• 78191-00-1 N-Methoxy-N-methylacetamide 
• 766-55-2 imidazo[1.2-b]pyridazine 
• 5469-70-5 3-aminopyridazine 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 

Downstream Products

• 453547-85-8 (4-imidazo[1,2-b]pyridazin-3-yl-pyrimidin-2-yl)-phenyl-amine 

Relevant articles and documents

Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors

Dual-specificity tyrosine-regulated kinase 1A (DYRK1A) regulates the proliferation and differentiation of neuronal progenitor cells during brain development. Consequently, DYRK1A has attracted interest as a target for the treatment of neurodegenerative diseases, including Alzheimer's disease (AD) and Down's syndrome. Recently, the inhibition of DYRK1A has been investigated as a potential treatment for diabetes, while DYRK1A's role as a mediator in the cell cycle has garnered interest in oncologic indications. Structure-activity relationship (SAR) analysis in combination with high-resolution X-ray crystallography leads to a series of pyrazolo[1,5-b]pyridazine inhibitors with excellent ligand efficiencies, good physicochemical properties, and a high degree of selectivity over the kinome. Compound 11 exhibited good permeability and cellular activity without P-glycoprotein liability, extending the utility of 11 in an in vivo setting. These pyrazolo[1,5-b]pyridazines are a viable lead series in the discovery of new therapies for the treatment of diseases linked to DYRK1A function.

NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS

The invention relates to 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture of the compounds according to the invention.

IMIDAZO[1,2-a]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS

The invention encompasses imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.